drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR-T)
drug_description
CRISPR-edited, allogeneic, second-generation anti-CD19 CAR-T (FMC63 scFv; CD28 costimulatory and CD3ζ signaling domains) with TRAC knockout to remove endogenous TCR and SPPL3 (Power3) knockout to alter glycosylation (“glycan shielding”), aiming to reduce GVHD, lessen alloimmune recognition, and improve persistence against CD19+ malignant B cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
CRISPR-edited, allogeneic second-generation anti-CD19 CAR-T cells (FMC63 scFv with CD28 costimulation and CD3ζ signaling) mediate CAR-driven activation and cytotoxic killing of CD19+ B cells. TRAC knockout removes the endogenous TCR to reduce graft-versus-host disease, while SPPL3 (Power3) knockout alters glycosylation to lessen alloimmune recognition and enhance persistence/expansion.
drug_name
ATHENA CAR-T (allogeneic anti-CD19 CAR-T with TRAC and SPPL3 knockouts)
nct_id_drug_ref
NCT06014073